Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Novo Nordisk unveiled the complete results of two late-stage trials for its weight-loss drug, CagriSema, indicating mainly mild to moderate side effects and favorable outcomes, including significant ...

(RTTNews) - Novo Nordisk's (NVO) Phase 3 REDEFINE 1 trial found that treatment with CagriSema led to a 22.7% weight loss at 68 weeks among patients who adhered to the treatment, compared to 2.3% ...

(Reuters) -Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome ...

CagriSema shows mild-to-moderate side effects in trials Researcher sees benefit to additional weight-loss options Novo Nordisk plans regulatory filing for CagriSema in early 2026 June 22 (Reuters ...

Top Alternatives to Ozempic That Are EffectiveReviewed by Dr. Craig Primack, MD, FACP, FAAP, FOMAOzempic is a medication approved by the FDA for individuals ...

In a separate 2017 case, Novo Nordisk agreed to pay $58.65 million to settle allegations that it failed to comply with FDA safety requirements for its Type 2 diabetes drug Victoza.

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that’s when a drug is prescribed for something it’s not FDA-approved for.

Two Massachusetts women have filed separate federal lawsuits against pharmaceutical giant Novo Nordisk, of Plainsboro, alleging the company’s popular weight-loss medication Wegovy caused them to ...